Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Leonardo G. Da Fonseca"'
Autor:
Loreto Boix, Víctor Sapena, Esther Samper, Álvaro Díaz-González, Neus Llarch, Gemma Iserte, Leonardo G. Da Fonseca, Marco Sanduzzi-Zamparelli, Alejandro Forner, Jordi Bruix, María Reig
Publikováno v:
Gastrointestinal Disorders, Vol 4, Iss 3, Pp 141-152 (2022)
Gastrointestinal adverse events (GIAEs) are common in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Diarrhea is a prevalent event responsible for treatment interruptions and dosage modifications. Our study evaluates th
Externí odkaz:
https://doaj.org/article/46e7da13fb49463898772c7a7112b9d5
Autor:
Leonardo G. da Fonseca, Laura Izquierdo-Sanchez, Pedro H. Hashizume, Estefanía Liza Beca, Yanina Carlino, Enrique Carrera, Marco Arrese, Javier Díaz Ferrer, Domingo Balderramo, Flair J. Carrilho, Andre Boonstra, Jose D. Debes, Claudia Pinto Marques Souza de Oliveira, Jesus M. Banales
Publikováno v:
Annals of Hepatology, Vol 24, Iss , Pp 100376- (2021)
Introduction: Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with dismal prognosis and increasing incidence. Information on epidemiology and risk factors are scarce, particularly in Latin America. Aim: Describe and analyze
Externí odkaz:
https://doaj.org/article/89648a0f10ac4da28426b1a3f5ca9461
Autor:
Leonardo G. Da Fonseca, Pedro H. Hashizume, Irai Santana de Oliveira, Laura Izquierdo-Sanchez, Lisa Rodrigues da Cunha Saud, Mariana Pinheiro Xerfan, Venancio Avancini Ferreira Alves, Evandro Sobroza de Mello, Paulo Herman, Jesus M. Banales, Claudia P. Oliveira, Flair J. Carrilho
Publikováno v:
Cancers, Vol 14, Iss 14, p 3483 (2022)
Introduction and objectives: The incidence of cholangiocarcinoma (CCA) has been increasing globally. Although a concomitant increase in the incidence of metabolic disorders might suggest a causal relationship, the data are scarce. We aimed to describ
Externí odkaz:
https://doaj.org/article/eb1ae075bb5148b4b37ce672b17ceafd
Autor:
Guilherme Nader Marta, Leonardo G. da Fonseca, Maria Ignez Braghiroli, Fernando Moura, Paulo M. Hoff, Jorge Sabbaga
Publikováno v:
Clinics, Vol 76 (2021)
OBJECTIVES: To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC). METHODS: We analyzed data from a cohort of patients with advanced HCC treated using systemic treatment according to the loc
Externí odkaz:
https://doaj.org/article/95db7a37cf154a989acb8cc5cdbfe5d6
Autor:
Franciele H. Knebel, Fabiana Bettoni, Leonardo G. da Fonseca, Anamaria A. Camargo, Jorge Sabbaga, Denis L. Jardim
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: Anti-EGFR antibodies are a standard care for advanced KRAS-wild type colorectal cancers. Circulating tumor DNA (ctDNA) monitoring during therapy can detect emergence of KRAS mutant clones and early resistance to therapy.Case Presentation:
Externí odkaz:
https://doaj.org/article/a4b9c81e2f4d41679ba68db65c0e065e
Autor:
Josep Corominas, Victor Sapena, Marco Sanduzzi-Zamparelli, Cristina Millán, Esther Samper, Neus Llarch, Gemma Iserte, Ferràn Torres, Leonardo G. Da Fonseca, Sergio Muñoz-Martínez, Alejandro Forner, Jordi Bruix, Loreto Boix, María Reig
Publikováno v:
Cancers, Vol 13, Iss 3, p 426 (2021)
Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant to assess the association between perip
Externí odkaz:
https://doaj.org/article/270dc578951d4a479b8e22602199b23c
Autor:
Marco Sanduzzi-Zamparelli, Loreto Boix, Maria Reig, Alejandro Forner, Carmen Ayuso, Gemma Iserte, Victor Sapena, Ernest Belmonte, Sergio Muñoz-Martínez, Cassia Guedes, Anna Darnell, Ferran Torres, Jordi Bruix, Leonardo G Da Fonseca, Jordi Rimola, Neus Llarch, Álvaro Díaz-González
Publikováno v:
United European Gastroenterology Journal
Background Despite atezolizumab and bevacizumab (A + B) is currently the first‐line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have
Autor:
Mercè Brunet, Anna Darnell, Loreto Boix, Josep Corominas, Gemma Iserte, Neus Llarch, Olga Millán, Ernest Belmonte, Ferran Torres, Maria Reig, Jordi Bruix, Carmen Ayuso, Leonardo G Da Fonseca, Victor Sapena, Marco Sanduzzi-Zamparelli, Esther Samper, Álvaro Díaz-González, Alejandro Forner
Publikováno v:
Liver International. 40:2476-2488
Background & aims Sorafenib and lenvatinib are the first-line treatments approved in hepatocellular carcinoma (HCC), but information is lacking about the relationships between their pharmacokinetics, patients pharmacogenetic profiles, adverse events
Autor:
Jordi Rimola, Alejandro Forner, Ramón Vilana, Carmen Ayuso, Luis Bianchi, Joana Ferrer, Álvaro Díaz-González, Ángeles García-Criado, Maria Reig, Carlos Rodríguez de Lope, Leonardo G Da Fonseca
Publikováno v:
Journal of Vascular and Interventional Radiology. 31:710-719
Purpose To assess the effectiveness, safety, and overall survival (OS) of thermal ablation as upfront treatment of intrahepatic colangiocarcinoma (ICC) in patients with cirrhosis. Materials and Methods This was a retrospective analysis of all biopsy-
Publikováno v:
Liver international : official journal of the International Association for the Study of the LiverREFERENCES. 42(2)